Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2018 Mar 27;11(1):206.
doi: 10.1186/s13071-018-2797-5.

Comparison of an injectable toltrazuril-gleptoferron (Forceris®) and an oral toltrazuril (Baycox®) + injectable iron dextran for the control of experimentally induced piglet cystoisosporosis

Anja Joachim  1 , Aruna Shrestha  2 , Barbara Freudenschuss  2 , Nicola Palmieri  2 , Barbara Hinney  2 , Hamadi Karembe  3 , Daniel Sperling  3
Affiliations
Randomized Controlled Trial

Comparison of an injectable toltrazuril-gleptoferron (Forceris®) and an oral toltrazuril (Baycox®) + injectable iron dextran for the control of experimentally induced piglet cystoisosporosis

Anja Joachim et al. Parasit Vectors. .

Abstract

Background: Cystoisospora suis causes diarrhoeal disease and reduced weight gain in suckling piglets, and a toltrazuril-based oral suspension is available for treatment. Recently a combinatorial product with toltrazuril plus iron has been developed for parenteral application. In this study we compared the efficacy of the injectable product with the oral suspension against experimentally induced piglet cystoisosporosis.

Methods: In a randomised controlled study, three groups of piglets (n = 10-13) were treated either with a fixed dose of 45 mg toltrazuril + 200 mg gleptoferron i.m. per piglet (Forceris®) on the second day of life (study day 2; SD 2) or with 20 mg toltrazuril/kg body weight as an oral suspension (Baycox® 5%) on SD 4 or left untreated (Control group). The Baycox® and the Control group received 200 mg of iron dextran/piglet on SD 2. All piglets were infected with 1000 sporulated C. suis oocysts on SD 3. Faecal samples were taken daily from SD 7 to SD 20 to determine faecal consistency, oocyst shedding and other diarrhoeal pathogens. Body weight was recorded on SD 1 and then weekly until SD 29. Animals were observed daily for general health and after treatment for possible adverse events.

Results: In the Control group all animals shed oocysts for 3.1 days on average and all animals showed diarrhoea for an average of five days. Excretion peaked on SD 9 (max. 48,618 oocysts per gram of faeces). Treatment with Forceris® completely suppressed oocyst excretion. In the Baycox® group, low levels of excretion could be detected. Diarrhoea was reduced to single piglets in the treated groups. Body weight development was reduced in the Control group compared to the treated groups. Enteropathogenic bacteria (Escherichia coli, Clostridium perfringens) could be detected. All parameters related to oocyst excretion, faecal consistency and weight gain were significantly improved in the treated groups compared to the Control group without significant differences between the treated groups. Both products were safe to use.

Conclusions: Treatment with both the injectable (Forceris®) and the oral (Baycox®) formulation of toltrazuril in the prepatent period were safe and highly effective against experimental infection with C. suis in newborn piglets.

Keywords: Coccidiosis; Cystoisospora suis; Diarrhoea; Efficacy; Experimental infection; Isospora suis; Pig; Swine; Toltrazuril.

PubMed Disclaimer

Conflict of interest statement

Ethics approval

The procedures involving piglets for collection of oocysts were approved by the institutional ethics committee and the national authority according to § 26ff of Animal Experiments Act, Tierversuchsgesetz 2012-TVG 2012 (license number: BMWF-68.205/0034-WF/V/3b/2016; Austrian Federal Ministry of Science, Health and Economy).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests. DS and HK are employees of Ceva. No member of the staff of the Vetmeduni Vienna involved in the trial received allowances or other personal benefits from the Sponsor.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Mean oocyst excretion given as ln (OpG+1) per group during the whole study period
Fig. 2
Fig. 2
Prevalence of McMaster countable excretion
Fig. 3
Fig. 3
Course of diarrhoea (FS 3 and 4) in the different groups
Fig. 4
Fig. 4
Course of the average faecal score (FS) in the different groups
Fig. 5
Fig. 5
Body weight development during the study (study days 1–29). Vertical lines depict the upper standard deviations
See this image and copyright information in PMC

References

    1. Stuart B, Lindsay D, Ernest J, Gosser H. Isospora suis enteritis in piglets. Vet Pathol. 1980;17:84–93. doi: 10.1177/030098588001700109. - DOI - PubMed
    1. Lindsay DS, Current WL, Taylor JR. Effects of experimentally induced Isospora suis infection on morbidity, mortality, and weight gains in nursing pigs. Am J Vet Res. 1985;46(7):1511–1512. - PubMed
    1. Lindsay DS, Current WL, Power TA. Enteric coccidial infections and coccidiosis in swine. Compend Contin Educ Vet. 1992;14:698–702.
    1. Martineau GP, del Castillo J. Epidemiological, clinical and control investigations on field porcine coccidiosis: clinical, epidemiological and parasitological paradigms? Parasitol Res. 2000;86(10):834–837. doi: 10.1007/PL00008509. - DOI - PubMed
    1. Niestrath M, Takla M, Joachim A, Daugschies A. The role of Isospora suis as a pathogen in conventional piglet production in Germany. J Vet Med B Infect Dis Vet Public Health. 2002;49(4):176–180. doi: 10.1046/j.1439-0450.2002.00459.x. - DOI - PMC - PubMed

Publication types

MeSH terms